Diabetic nephropathy is the result of pathophysiological mechanisms whose best knowledge has offered new therapeutic
possibilities and a better life expectancy for both type 1 and type 2 diabetes. Nevertheless, the diabetic kidney may be the seat of
other lesions. This is due to diabetics whose positive diagnosis is based on renal biopsy, which is certainly an invasive means but will
allow etiological therapeutic management other than glycemic control. diabetic nephropathy is a chronic pathology which therefore
requires non-invasive monitoring means that will allow us not only to determine the rate of progression of diabetic kidney disease
but also to indicate screening for previously undiagnosed non-diabetic renal lesion. for this reason, biological and morphological
means are necessary whose cost-benefit ratio is necessary before their standardization by targeting a certain diabetic population
thus allowing to act at an earlier stage before the installation of irreversible lesions.